Brief: Sage Therapeutics Rejects Biogen's $7.22 Per Share Acquisition Proposal
27/01/2025 14:22
Jan 27 (Reuters) - SAGE Therapeutics Inc SAGE.O :
* SAGE THERAPEUTICS BOARD OF DIRECTORS INITIATES REVIEW OF
STRATEGIC ALTERNATIVES AND REJECTS BIOGEN’S UNSOLICITED
ACQUISITION PROPOSAL
* SAGE THERAPEUTICS INC - REJECTS BIOGEN'S $7.22 PER SHARE
ACQUISITION PROPOSAL
* SAGE THERAPEUTICS INC - CONCLUDES PROPOSAL FROM BIOGEN
SIGNIFICANTLY UNDERVALUES CO
Source text: ID:nBw2Dlncha
Further company coverage: SAGE.O
(Reporting by Siddhi Mahatole)
((SiddhiPrabhanjan.Mahatole@thomsonreuters.com;))
Recent news on Sage Therapeutics
See all newsBrief: Supernus Pharmaceuticals Completes Acquisition Of Sage Therapeutics
Sage Therapeutics Inc Reports Results For The Quarter Ended June 30: Earnings Summary
SAGE Therapeutics Q2 revenue rises sequentially
Brief: Supernus Pharmaceuticals Announces Expiration Of Hart-Scott-Rodino Waiting Period For Sage Therapeutics Tender Offer
Sage Therapeutics Inc Expected To Post A Loss Of 95 Cents A Share: Earnings Preview